The efficiency of antiviral therapy in patients with chronic hepatitis C infected with hepatitis C virus recombinants

Yushchuk N.D.; Znoiko O.O.; Dudina K.R.; Kozina A.N.; Kalininа O.V.

doi:https://doi.org/10.17116/terarkh2016886101-105

Yushchuk N.D.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Znoiko O.O.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Dudina K.R.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Kozina A.N.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Kalininа O.V.

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia

The efficiency of antiviral therapy in patients with chronic hepatitis C infected with hepatitis C virus recombinants

Authors:

Yushchuk N.D., Znoiko O.O., Dudina K.R., Kozina A.N., Kalininа O.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(6): 101‑105

DOI: 10.17116/terarkh2016886101-105

Read: 1809 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Yushchuk ND, Znoiko OO, Dudina KR, Kozina AN, Kalininа OV. The efficiency of antiviral therapy in patients with chronic hepatitis C infected with hepatitis C virus recombinants. Therapeutic Archive. 2016;88(6):101‑105. (In Russ.)
https://doi.org/10.17116/terarkh2016886101-105

Использование инфографики авторами научных работ

Close metadata

Abstract:

The review gives the data available in the literature on the efficiency of treatment in patients with chronic hepatitis C infected with hepatitis C virus (HCV) recombinants, by applying various antiviral therapy regimens. The low efficiency of treatment with pegylated interferons (PEG IFN) + ribavirin (RIB) and sofosburin (SOF) + RIB in this patient group (a sustained virologic response was achieved in 22 and 30.7%, respectively) compared with the efficiency of treatment (87—97 and 83—97%, respectively) in patients infected with HCV genotype 2 does not allow the 2015 EASL HCV genotype 2 treatment regimens to be used in such patients. In this connection, subtyping genotype 2 isolates by NS5B sequencing should be introduced into clinical laboratory practice to successfully detect recombinant HCVs and to enhance the efficiency of antiviral therapy.

Keywords:

hepatitis C virus recombinants

RF2k/1b

chronic hepatitis C

antiviral therapy

NS5B sequencing

Authors:

Yushchuk N.D.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Znoiko O.O.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Dudina K.R.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Kozina A.N.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Kalininа O.V.

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia

Close metadata

References:

World Health Organization. Hepatitis C. Fact sheet N 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed November, 2015.
Nevens F, Colle I, Michielsen P, Robaeys G, Moreno C, Caekelbergh K, Lamotte M, Wyffels V. Resource use and cost of hepatitis C-related care. Eur J Gastroenterol Hepatol. 2012;24(10):1191-1198. doi:10.1097/MEG.0b013e3283566658.
Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-548. doi:10.1016/j.bpg.2012.09.010.
Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(1):74-81. doi:10.1111/j.1478-3231.2008.01934.x.
World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ Accessed November, 2015.
Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89-96. doi:10.1016/j.antiviral.2015.01.004.
Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ. Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences of USA. 1991;88(6):2451-2455. doi:10.1073/pnas.88.6.2451.
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318-327. doi:10.1002/hep.26744.
Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, Drenth JP, McHutchison JG, Brainard D, Stamm LM, Miller MD, Svarovskaia E, Mo H. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology. 2015;61(2):471-480. doi:10.1002/hep.27361.
Kalinina O, Norder H, Mukomolov S, Magnius LO.A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76(8):4034-4043. doi:10.1128/jvi.76.8.4034-4043.2002.
Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimägi L, Magnius LO.Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol. 2007;79(4):374-382. doi:10.1002/jmv.20828.
Samokhvalov E, Nikolaeva L, Al'khovskiĭ S, Khlopova V, Petrova E, Sapronov G, Beliaeva N, L'vov D. Frequency of detection of different hepatitis C virus subtypes in the Moscow region. Voprosy Virusologii. 2013;58(1):36-40. (In Russ.)
Chub E, Kochneva G, Granitov V, Netesov S. Recombinants of hepatitis C virus type 2k /1b in the population of the Altai region. Infektsionnye bolezni. 2007;5(4):5-11. (In Russ.)
Raghwani J, Thomas XV, Koekkoek SM, Schinkel J, Molenkamp R, van de Laar TJ, Takebe Y, Tanaka Y, Mizokami M, Rambaut A, Pybus OG. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol. 2012;86(4):2212-2220. doi:10.1128/JVI.06184-11.
Newman RM, Kuntzen T, Weiner B, Berical A, Charlebois P, Kuiken C, Murphy DG, Simmonds P, Bennett P, Lennon NJ, Birren BW, Zody MC, Allen TM, Henn MR. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect Dis. 2013;208(1):17-31. doi:10.1093/infdis/jis679.
Kalinina O. Genome organization and geographical distribution of the natural intergenotypic recombinant of hepatitis C virus RF1_2k/1b. Infektsiya I immunitet. 2012;2(4):677-686. (In Russ.) doi:10.15789/2220-7619-2012-4-677-686.
Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res. 2015:1-7. doi:10.1111/hepr.12505.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593. doi:10.1056/NEJMoa0808010.
Gower E, Estes C, Blach S, Razavi-Shearer K1, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57. doi:10.1016/j.jhep.2014.07.027.
Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region:a review of datafocusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142(2):270-286. doi:10.1017/S0950268813000940.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initialtreatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965. doi:10.1016/s0140-6736(01)06102-5.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982. doi:10.1056/nejmoa020047.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355. doi:10.7326/0003-4819-140-5-200403020-00010.
Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buh M, Nieminen U, Nuutinen H, Alsiö Å,Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scand J Gastroenterol. 2016;51(3):337-343. doi:10.3109/00365521.2015.1087588.
Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, Mazzoni E, Bonaventura ME, Nosotti L, Arcuri P, Picardi A, Barbarini G, D'Ambrosio C, Paffetti A, Andreoli A, Soccorsi F. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virusgenotype 2 or 3: the cleo trial. BMC Gastroenterol. 2010;10:21. doi:10.1186/1471-230X-10-21.
Kalinina O, Znoiko O, Isagulyants M. Natural recombinant of hepatitis C virus RF1_2k/1b: clinical and epidemiological significance. IV International Congress on Infectious Diseases; March 26—28, 2012; Moscow. Available at: http://www.congress-infection.ru/archiv.htm. Accessed November, 2015. (In Russ.)
Morel V, Descamps V, François C, Fournier C, Brochot E, Capron D, Duverlie G, Castelain S. Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report. J Clin Virol. 2010;47(4):382-386. doi:10.1016/j.jcv.2010.01.011.
Nikolaeva L, Smirnov G, Kolotvin A, Samohvalov E ,Leybman E, Samokhodskaya L. Hepatitis C in infection with recombinant strain RF2K/1B of the virus: clinical course and therapy. Epidemiologiay i infektsionnye bolezni. 2014;3:9-15. (In Russ.)
Ramière C, Tremeaux P, Caporossi A, Trabaud MA, Lebossé F, Bailly F, Thélu MA, Nana J, Leroy V, Morand P, André P, Larrat S. Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment. Euro Surveill. 2014;19(43):20944. doi:10.2807/1560-7917.es2014.19.43.20944.
EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373-395. doi:10.1016/j.jhep.2014.05.001.
De Keukeleire S, Descheemaeker P, Reynders M. Diagnosis of hepatitis C virus genotype 2k/1b needs NS5B sequencing. Int J Infect Dis. 2015;41:1-2. doi:10.1016/j.ijid.2015.10.010.
EASL Recommendations on Treatment of Hepatitis C 2015. European Association for Study of Liver. J Hepatol. 2015;63(1):199-236. doi:10.1016/j.jhep.2015.03.025.